NCT03747497

Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil Compared to Linezolid Administered Intravenously and Orally to Adult Subjects With Acute Bacterial Skin and Skin Structure Infection

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 196 (actual)
• Sponsor: MicuRx · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether contezolid acefosamil is as safe and effective as linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections

Conditions

• Skin Diseases, Bacterial
• Gram-Positive Bacterial Infections

Interventions

Type	Name	Description
DRUG	contezolid acefosamil	IV and oral contezolid acefosamil given twice a day for 10 to 14 days
DRUG	linezolid 600 mg	IV and oral linezolid given twice a day for 10 to 14 days

Timeline

• Start date: 2018-11-15
• Primary completion: 2019-03-26
• Completion: 2019-03-26
• First posted: 2018-11-20
• Last updated: 2022-11-08
• Results posted: 2021-04-30

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study